Abstract
A novel coronavirus, SARS- CoV-2 (2019-nCoV), emerged in December 2019 as an immediate global challenge. Comprehensive efforts at the present time are focused simultaneously on containing the spread of this virus and extenuating the ill effects. There is an immediate need for drugs that can help before a vaccine can be developed. Researchers are endeavoring to find antiviral therapies specific to the virus. As the condition is an emerging, rapidly evolving situation and development of new drugs is a long process, and is unfeasible to face the immediate global challenge. Strategy to reposition the previously used drugs can prove to be effective to combat this difficult to treat pandemic. Several drugs such as Hydroxychloroquine, Umifenovir, Remdesivir, Lopinavir/ Ritonavir, interferon, Darunavir, Favipiravir, Nitazoxanide, etc. are currently undergoing clinical studies to test the safety and efficacy of the drug against this pandemic. The present review gives a snapshot look at the current clinical experience with repurposed antiviral drugs.
Keywords: COVID-19, 2019-nCoV, SARS- CoV-2, novel coronavirus, repurposed drugs, antiviral therapies.
Infectious Disorders - Drug Targets
Title:Pharmacological Strategies for COVID-19 - A Review of the Most Promising Repurposed Antiviral Drugs
Volume: 21 Issue: 7
Author(s): Deepti Chopra, Jaspreet K Boparai, Bharti Bhandari*, Anurag Srivastava and Rakesh Gupta
Affiliation:
- Department of Physiology, Government Institute of Medical Sciences, Greater Noida, Uttar Pradesh,India
Keywords: COVID-19, 2019-nCoV, SARS- CoV-2, novel coronavirus, repurposed drugs, antiviral therapies.
Abstract: A novel coronavirus, SARS- CoV-2 (2019-nCoV), emerged in December 2019 as an immediate global challenge. Comprehensive efforts at the present time are focused simultaneously on containing the spread of this virus and extenuating the ill effects. There is an immediate need for drugs that can help before a vaccine can be developed. Researchers are endeavoring to find antiviral therapies specific to the virus. As the condition is an emerging, rapidly evolving situation and development of new drugs is a long process, and is unfeasible to face the immediate global challenge. Strategy to reposition the previously used drugs can prove to be effective to combat this difficult to treat pandemic. Several drugs such as Hydroxychloroquine, Umifenovir, Remdesivir, Lopinavir/ Ritonavir, interferon, Darunavir, Favipiravir, Nitazoxanide, etc. are currently undergoing clinical studies to test the safety and efficacy of the drug against this pandemic. The present review gives a snapshot look at the current clinical experience with repurposed antiviral drugs.
Export Options
About this article
Cite this article as:
Chopra Deepti , Boparai K Jaspreet, Bhandari Bharti *, Srivastava Anurag and Gupta Rakesh , Pharmacological Strategies for COVID-19 - A Review of the Most Promising Repurposed Antiviral Drugs, Infectious Disorders - Drug Targets 2021; 21 (7) : e160921189260 . https://dx.doi.org/10.2174/1871526520666201218151841
DOI https://dx.doi.org/10.2174/1871526520666201218151841 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intracellular Amyloid β-Protein As a Therapeutic Target for Treating Alzheimers Disease
Current Alzheimer Research Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research DNA Microarrays - An Armory for Combating Infectious Diseases in the New Century
Infectious Disorders - Drug Targets Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets Targeting Generation of Antibodies Specific to Conformational Epitopes of Amyloid β-Derived Neurotoxins
CNS & Neurological Disorders - Drug Targets An Inducible Expression System for Recombinant Sca Proteins with an Autotransporter Domain from <i>Orientia Tsutsugamushi in Escherichia coli</i>
Protein & Peptide Letters Efficacy and Toxicity of Clioquinol Treatment and A-beta42 Inoculation in the APP/PSI Mouse Model of Alzheimer's Disease
Current Alzheimer Research The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimers Disease
Current Topics in Medicinal Chemistry From Alpha to Omega with Aβ: Targeting the Multiple Molecular Appearances of the Pathogenic Peptide in Alzheimers Disease
Current Medicinal Chemistry Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Multivalent & Multifunctional Ligands to β-Amyloid
Current Pharmaceutical Design Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
Current Neuropharmacology Anti-Amyloid Treatments in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Antibody Responses, Amyloid-β Peptide Remnants and Clinical Effects of AN-1792 Immunization in Patients with AD in an Interrupted Trial
CNS & Neurological Disorders - Drug Targets An Update on Autoinflammatory Diseases
Current Medicinal Chemistry Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews Dynamics of T Cells Repertoire During Trypanosoma cruzi Infection and its Post-Treatment Modulation
Current Medicinal Chemistry Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Parvovirus B19 (B19V) Infection and Pregnancy
Current Pediatric Reviews